Karlin Daniel 4

What Happened

• Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), was granted 100,000 common shares (transaction code A — award/grant) on June 22, 2026. The reported acquisition price is $0.00, reflecting that these are performance-based awards rather than a market purchase.
• The award represents the first tranche of performance share units (PSUs) tied to clinical and regulatory milestones; vesting is subject to continued employment through March 12, 2028 and achievement of the specified milestones. There is no immediate cash value or sale proceeds from this transaction.

Key Details

• Transaction date and price: 2026-06-22; 100,000 shares @ $0.00 (award/grant).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: These 100,000 shares are the first tranche of PSUs granted effective March 12, 2025; each PSU is a contingent right to one common share upon meeting clinical/regulatory milestones and service through March 12, 2028.
• Filing timeliness: Form 4 filed the same day (no late filing indicated in the provided information).

Context

• Performance share units are contingent compensation: they do not represent immediately vested, tradable stock and will convert to common shares only if both service and milestone conditions are met.
• Such awards are a routine part of executive compensation and are not the same signal as an outright purchase (which some investors view as a stronger bullish indicator).